Embryo Selection by Noninvasive Preimplantation Genetic Test

NCT04339166 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1152

Last updated 2025-12-11

No results posted yet for this study

Summary

The objective of this study is to explore whether non-invasive chromosome screening (NICS) can be used as an effective indicator for embryos selection besides morphology through a multicenter randomized controlled trial, by comparing the differences of live birth rate, pregnancy rate and miscarriage rate between the two groups of embryo selection by "NICS+ morphology" and embryo selection only by "morphology" in IVF cycle.

Conditions

Interventions

DIAGNOSTIC_TEST

Non-invasive chromosome screening(NICS)

NICS is noninvasive chromosome screening approach to analysis the euploidy by free DNA in embryo culture medium

Sponsors & Collaborators

  • Jinling Hospital, China

    collaborator OTHER
  • Reproductive Medical Center of Hebei Maternity Hospital

    collaborator UNKNOWN
  • Northwest Women's and Children's Hospital, Xi'an, Shaanxi

    collaborator OTHER
  • The First Medical Center of Chinese People's Liberation Army General Hospital

    collaborator UNKNOWN
  • Shengjing Hospital

    collaborator OTHER
  • First Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER
  • Reproductive & Genetic Hospital of CITIC-Xiangya

    collaborator OTHER
  • Yikon Genomics Company, Ltd

    collaborator UNKNOWN
  • Peking University Shenzhen Hospital

    collaborator OTHER
  • The Second Hospital of Hebei Medical University

    collaborator OTHER
  • West China Second University Hospital

    collaborator OTHER
  • Second Affiliated Hospital of Wenzhou Medical University

    collaborator OTHER
  • Third Affiliated Hospital of Zhengzhou University

    collaborator OTHER
  • Peking University Third Hospital

    lead OTHER

Principal Investigators

  • Jie Qiao · Peking University Third Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-16
Primary Completion
2024-02-28
Completion
2024-08-06

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04339166 on ClinicalTrials.gov